United Kingdom

People: VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

19 Oct 2018
Change (% chg)

$0.09 (+4.27%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Snodgrass, H. 

Dr. H. Ralph Snodgrass, Ph.D, is the President, Chief Scientific Officer, Director of Vistagen Therapeutics, Inc. He co-founded VistaGen with Dr. Gordon Keller in 1998 and served as our Chief Executive Officer until August 2009. Dr. Snodgrass has served as our President and Chief Scientific Officer since August 2009. He has served as a member of our Board of Directors since 1998. Prior to founding VistaGen, Dr. Snodgrass served as a key member of the executive management team which lead Progenitor, Inc., a biotechnology company focused on developmental biology, through its initial public offering, and was its Chief Scientific Officer from June 1994 to May 1998, and its Executive Director from July 1993 to May 1994. He received his Ph.D. in immunology from the University of Pennsylvania, and has 20 years of experience in senior biotechnology management and over 10 years research experience as a professor at the Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill School of Medicine, and as a member of the Institute for Immunology, Basel, Switzerland. Dr. Snodgrass is a past Board Member of the Emerging Company Section of the Biotechnology Industry Organization (BIO), and past member of the International Society Stem Cell Research Industry Committee. Dr. Snodgrass has published more than 50 scientific papers, is the inventor on more than 17 patents and a number of patent applications, is, or has been, the principal investigator on U.S. federal and private foundation sponsored research grants with budgets totaling more than $14.5 million and is recognized as an expert in stem cell biology with more than 20 years’ experience in the uses of stem cells as biological tools for drug discovery and development.

Basic Compensation

Total Annual Compensation, USD 305,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 458,700
Fiscal Year Total, USD 763,700

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

H. Snodgrass


Shawn Singh


Jerrold Dotson


Mark Smith


Jerry Gin


Jon Saxe

As Of  31 Mar 2015